- Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002)Shen, Lin; Liu, Dan; Li, Ning; Guo, Weijian; Liu, Tianshu; Li, Hongli; Li, Jiayi; Bai, Yuxian; Deng, Yanhong; Zhuang, Zhi-xiang; Sun, Meili; Fan, Qingxia; Zhao, Fuyou; Han, Liang; Xia, Zhenzhong; Wang, Jianming; Qi, Charlie; Xu, Li; Qian, Xueming; Germa, CarolineAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer.Xu, Rui-Hua; Ruan, Dan-Yun; Zhang, Dong-Sheng; Liu, Fu-Rong; Luo, Su-Xia; Zhuang, Zhi-Xiang; Wang, Zhen-Ning; Liu, Fu-Nan; Zhang, Yan-Qiao; Yang, Jian-Wei; Chen, Zhen-Dong; Wang, Yong-Sheng; Wang, Jun-Ye; Liang, Xiao-Hua; Wu, Xiao-Jie; Zheng, Yu-Long; Liu, Jian; Shi, Xi; Liu, Wei; Chen, BoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2023-11 To 2023-11.
- KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1-selected populationsRha, Sun Young; Wyrwicz, Lucjan; Weber, Patricio Eduardo Yanez; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Rivera, Fernando; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernandez, Manuel Gonzalez; Li, Jin; Lowery, Maeve Aine; Cil, Timucin; Cruz, Felipe Melo; Qin, Shukui; Yin, Lina; Bordia, Sonal; Bhagia, Pooja; Oh, Do-YounAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 4
会议论文
Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first-line treatment of advanced G/GEJ cancer - updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort C
4阅读
